Aripiprazole

SGA • Brands: Abilify

Last reviewed: 2025-09-23

General information

Indicated for: Aripiprazole is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia ( 14.1 ) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I ( 14.2 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette’s disorder ( 14.5 )

Dosing & forms

Forms/strengths: —
Frequency: —
Food: —
Typical range: 10–30 mg/day

Mechanism (brief)

Partial agonist at dopamine D2 and serotonin 5-HT1A; antagonist at 5-HT2A receptors.

Metabolism & Half‑life

Metabolism: CYP2D6 and CYP3A4, active metabolite dehydro-aripiprazole.
Half‑life: ~75 h (up to ~146 h in CYP2D6 poor metabolizers).

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Long‑acting injectable (LAI)

Aripiprazole monohydrate

Interval: Monthly (q4wk)
Oral overlap: Yes — typically 14 days
Site: Deltoid or gluteal

Citations

Label DOI PMCID

Aripiprazole lauroxil

Interval: q4–8wk (varies by strength)
Oral overlap: Yes — typically 21 days (unless using Initio loading)
Site: Deltoid or gluteal

Citations

Label Label DOI

Monitoring highlights

Metabolic: weight, BMI, fasting lipids/glucose — Baseline, 3 mo, annually

Sources

Aripiprazole label — DailyMed (2025)